MBX (MBX Biosciences) Total Equity: $437.76 Mil (As of Mar. 2026)


MBX MBX Biosciences Inc MBX
12 GF Score
Price $51.90
! 2 Warning Signs
View Full Analysis

What is MBX Biosciences Total Equity?

MBX Biosciences MBX +2.96% 12 Total Equity is $437.76 Mil as of Mar. 2026. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

MBX Biosciences's total equity for the quarter that ended in Mar. 2026 was $437.76 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

MBX Biosciences Total Equity Historical Data

* Premium members only.

The historical data trend for MBX Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MBX Biosciences Total Equity Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Equity
-42.61 -72.47 257.44 369.22

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 235.42 219.24 387.54 369.22 437.76
MBX
12GF Score
MBX Biosciences Inc MBX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MBX Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

MBX Biosciences's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=385.144-15.921
=369.22

MBX Biosciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=452.701-14.945
=437.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $437.76 Mil mean?
MBX Biosciences (MBX) has a Total Equity of $437.76 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for MBX Biosciences and its competitors.
Is MBX Biosciences' Total Equity too high?
MBX Biosciences' current Total Equity is $437.76 Mil. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' Total Equity compare to ARDX and INBX?
MBX Biosciences' Total Equity of $437.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for MBX Biosciences and its competitors. MBX Biosciences's current Total Equity is $437.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current Total Equity of $437.76 Mil. The current Total Equity is $437.76 Mil. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For MBX Biosciences (MBX), the current Total Equity is $437.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MBX Biosciences Business Description

Address 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score

Get the complete analysis for MBX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$51.90
Price